» Articles » PMID: 20022823

Descriptive Epidemiology of Cholangiocarcinoma in Italy

Overview
Journal Dig Liver Dis
Publisher Elsevier
Specialty Gastroenterology
Date 2009 Dec 22
PMID 20022823
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Very little data exist on the epidemiology of cholangiocarcinoma in Italy.

Aim: We focus on the descriptive epidemiology of cholangiocarcinoma in Italy.

Methods: Data on incidence were obtained from the Italian Association of Tumour Registries while mortality data were obtained from the Italian National Institute of Statistics.

Results: A progressive increase of incidence with age was seen for extra-hepatic, intra-hepatic and not otherwise specified cholangiocarcinoma. Crude incidence rates were higher for extra-hepatic cholangiocarcinoma than those for intra-hepatic cholangiocarcinoma and in men compared to women. An increasing incidence trend was observed, from 1988 to 2005, for both extra-hepatic- and intra-hepatic cholangiocarcinoma with a 3-6% yearly increase and with a rate of increase higher for men than for women and for intra-hepatic- than for extra-hepatic cholangiocarcinoma. For intra-hepatic cholangiocarcinoma, the mortality rates progressively increased from 0.15 per million in 1980 to 5.9 per million in 2003, when mortality for this cancer surpassed extra-hepatic cholangiocarcinoma. Mortality rates for extra-hepatic cholangiocarcinoma showed an increasing trend from 1980 to 1994 but, in contrast to intra-hepatic cholangiocarcinoma, a stable or slightly decreasing trend from 1995 to 2003 was observed.

Conclusions: In Italy, cholangiocarcinoma showed a progressive increase in incidence and mortality in the last two decades mainly in intra-hepatic cholangiocarcinoma.

Citing Articles

Simultaneous embolization of the right portal and hepatic veins before intrahepatic cholangiocarcinoma resection.

Amorim A, Fonseca Neto O, Furtado R, Batista L, Costa L, Galvao I Einstein (Sao Paulo). 2024; 22:eRC0524.

PMID: 39504092 PMC: 11634352. DOI: 10.31744/einstein_journal/2024RC0524.


The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials.

Vitale E, Rizzo A, Maistrello L, Nardulli P, Talienti T, Quaresmini D Front Oncol. 2024; 14:1409132.

PMID: 39091909 PMC: 11291215. DOI: 10.3389/fonc.2024.1409132.


Cholangiocarcinoma and Occupational Exposure to Asbestos: Insights From the Italian Pooled Cohort Study.

Curti S, Gallo M, Ferrante D, Bella F, Boschetti L, Casotto V Med Lav. 2024; 115(2):e2024016.

PMID: 38686579 PMC: 11181221. DOI: 10.23749/mdl.v115i2.14649.


Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.

Conci S, Catalano G, Roman D, Zecchetto C, Lucin E, De Bellis M Int J Med Sci. 2023; 20(7):858-869.

PMID: 37324191 PMC: 10266048. DOI: 10.7150/ijms.82008.


Trends in Liver Cancer Incidence and Survival in Italy by Histologic Type, 2003-2017.

Mancini S, Bucchi L, Zamagni F, Guzzinati S, Dal Maso L, Rugge M Cancers (Basel). 2022; 14(24).

PMID: 36551647 PMC: 9777051. DOI: 10.3390/cancers14246162.